Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) Director N Anthony Coles sold 2,506 shares of Cerevel Therapeutics stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $41.54, for a total value of $104,099.24. Following the sale, the director now owns 15,638 shares of the company’s […]
John Renger Sells 2,161 Shares of Cerevel Therapeutics Holdings, Inc (NASDAQ:CERE) Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) insider John Renger sold 2,161 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $41.54, for a total transaction of $89,767.94. Following the sale, the insider now directly owns 6,370 shares of […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) Director N Anthony Coles sold 2,506 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $41.54, for a total transaction of $104,099.24. Following the transaction, the director now owns 15,638 shares in the company, valued […]
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.